On March 4, 2021 the Journal of the American Medical Association (JAMA) published results from a clinical trial on ivermectin in COVID-19. The study found no benefit of the drug in patients with mild disease for time to symptom resolution. The authors suggested that results from their study may indicate ineffectiveness of ivermectin beyond time to symptom resolution:
“…although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.”
One controversial aspect to this study has been the title of the study protocol. The final title was “Double blind, randomized, controlled clinical trial to investigate the effectiveness of the D11AX22 molecule in adult subjects from Valle del Cauca with initial stages of infection by SARS CoV2 / COVID19.” Since the term “D11AX22 molecule” was used in the title of the study protocol it is possible that that term was also used in the consent form.
The use of ivermectin in COVID-19 in Cali, Colombia, the location of the study, was increasing at the time of the study. On July 10, 2020, the mayor of Cali, Jorge Iván Ospina, announced the distribution of 10,000 doses of ivermectin i...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).